RT @radonconeuro: #elderly #gliomas Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating…
#elderly #gliomas Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. https://t.co/2xPsJdNxMu
RT @sean_sachdev: European GBM pts followed w/ FET-PET/MRI after Optune/TTF based treatments. Some improvement seen with optune monotherapy…
RT @sean_sachdev: European GBM pts followed w/ FET-PET/MRI after Optune/TTF based treatments. Some improvement seen with optune monotherapy…
RT @sean_sachdev: European GBM pts followed w/ FET-PET/MRI after Optune/TTF based treatments. Some improvement seen with optune monotherapy…
RT @sean_sachdev: European GBM pts followed w/ FET-PET/MRI after Optune/TTF based treatments. Some improvement seen with optune monotherapy…
This is really cool. Notice the absence of contrast enhancement. Was it IDH positive? @CraigHorbinski Is there any way to include some vasculogenesis marker with IDH positivity? If you see the scans, there’s no contrast enhancement. https://t.co/WW05K
RT @sean_sachdev: European GBM pts followed w/ FET-PET/MRI after Optune/TTF based treatments. Some improvement seen with optune monotherapy…
RT @sean_sachdev: European GBM pts followed w/ FET-PET/MRI after Optune/TTF based treatments. Some improvement seen with optune monotherapy…
RT @sean_sachdev: European GBM pts followed w/ FET-PET/MRI after Optune/TTF based treatments. Some improvement seen with optune monotherapy…
European GBM pts followed w/ FET-PET/MRI after Optune/TTF based treatments. Some improvement seen with optune monotherapy. PET reliably distinguished treatment effect from tumor progression. PET/MR now here @NUradiology #gbm #glioblastoma #btsm https://t.c
#newupdatesneuroonc #braintumours #neuroonc Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. - https://t.co/vDLc8dtblZ